Covid-19

Covid-19 vaccines – Time to reset the impact bar

Covid-19 vaccines – Time to reset the impact bar

Oct 15, 2021

Even more concerning is the approval of the DNA vaccine of Cadila Healthcare in India for children in the 12-18 age group based on a small subset of data, without biodistribution studies and without evaluation of long-term safety aspects in children.

World Sight Day: Experts advocate significance of regular eye health checkup

World Sight Day: Experts advocate significance of regular eye health checkup

Oct 14, 2021

The pandemic has had a severe impact on provision of eye care facilities across the country which further led to increasing cases of eye problems.

Pediatricians hail SEC approval for EUA to Covaxin for 2 to 18 age group for timely immunization 

Pediatricians hail SEC approval for EUA to Covaxin for 2 to 18 age group for timely immunization 

Oct 12, 2021

Covaxin, indigenously developed by BBIL in collaboration with the Indian Council of Medical Research (ICMR), is being used on adults in India’s ongoing COVID-19 vaccination drive.

Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose COVID vaccine

Cadila Healthcare gets DCGI nod to conduct phase III trials for two-dose COVID vaccine

Oct 05, 2021

The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20.

India to soon roll out clinical trials on 750 hospitalised adult patients as part WHO Solidarity trial

India to soon roll out clinical trials on 750 hospitalised adult patients as part WHO Solidarity trial

Oct 05, 2021

The WHO Solidarity PLUS Trial aims to evaluate three treatment arms -Artesunate, Infliximab and Imatinib, in addition to the local standard of care.

Pediatricians and experts share concerns around availability, affordability of children vaccine

Pediatricians and experts share concerns around availability, affordability of children vaccine

Oct 04, 2021

Though efficacy of ZyCoV-D was 67% compared to mRNA vaccine and others which is about 90%, there have not been late stage trials which Zydus Cadila has promised to publish at a later date.